top of page
News, Events and Updates
Search
Sep 14, 2011
Anavex to Present Data on ANAVEX 2-73, Lead Compound for Alzheimer's Disease
Jul 25, 2011
Anavex Presents Data on Neuroprotective Evidence for ANAVEX 2-73, Lead Compound for AD
Jul 24, 2011
Anavex Presents Data on Potential Dual Utility of ANAVEX 2-73 in Both Amyloid and Tau Pathology
Jul 15, 2011
Preclinical Development of New Tetrahydrofuran Derivatives Targeting the Sigma-1 Chaperone Protein
Jul 15, 2011
The novel tetrahydrofuran derivative ANAVEX2-73 attenuated GSK-3β activation and Tau...
Jul 14, 2011
Anavex to Present at Alzheimer's Association International Conference on Alzheimer's Disease
Jul 10, 2011
Anavex Raises $1.575 million
Jul 5, 2011
Anavex Rapidly Advances ANAVEX 2-73 for Alzheimer’s Disease, Phase I Clinical Trial Progressing Well
Jun 7, 2011
Anavex Advances Second Lead Compound; Initiates Scale-Up Manufacturing of ANAVEX 1-41
May 22, 2011
ANAVEX 2-73 Advances Phase I Clinical Trial for Alzheimer’s Disease
May 16, 2011
Anavex Comments on New Alzheimer’s Disease Diagnostic Guidelines
42
43
44
45
46
Stay Connected
Follow us on social media
Newsroom
Webcast Library
Contact Us
Back to Newsroom
bottom of page
